Provides an overview of the interim results for the 2026 fiscal year, progress on the iPS drug discovery business, and discusses segments, outlook, and capital policy\/dividend policy, which are not yet disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4896","jir_company_name":"K-Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4896-20260819-01.pdf","jir_short_summary":"Provides an overview of the interim results for the 2026 fiscal year, progress on the iPS drug discovery business, and discusses segments, outlook, and capital policy\/dividend policy, which are not yet disclosed.","jir_summary":"### Section Heading\nThis document is a financial summary that\u6574\u7406s the interim results and strategy for fiscal year 2026, with a focus on the current status and future prospects of the iPS drug discovery business. Key points include business composition, progress in research and development, timeline for clinical development, and status of partnerships and collaborations.\n\n### Second Section Heading\nIncludes information that supplements progress by business segment and its financial impact, the upcoming R&D roadmap, and unresolved items regarding capital policy and shareholder return policy. In particular, emphasizes technology challenges, competitive landscape, and collaboration strategy for the iPS drug discovery business.","jir_financial_highlights":"Sales: Unknown (Unknown)\nOperating income: Unknown (Unknown)\nNet income: Unknown (Unknown)","jir_category":"","jir_hashtags":"#ExcludeFixedTagsForKPharma #IR-specific themes such as share buyback or executive appointments are not included","jir_key_figures":"Sales: Unknown\nOperating income: Unknown\nTotal equity: Unknown","jir_meta_title":"K-Pharma Co., Ltd. 2026 Interim Earnings Summary | Key Points","jir_meta_description":"Summary of the key points from K-Pharma Co., Ltd.'s 2026 interim earnings summary. Includes business strategy, progress in the iPS drug discovery business, outlook, and important financial indicators; where data is unavailable, it is noted as Unknown in the PDF.","jir_og_title":"K-Pharma Co., Ltd. Interim Earnings Summary | iPS Drug Discovery Progress","jir_og_description":"K-Pharma's interim earnings summary document. Explains progress and future roadmap for the iPS drug discovery business and trends by segment. Financial figures may be unknown.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59253,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-105316","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n